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1. Introduction 
Psoriatic arthritis (PsA) was first recognized as a specific rheumatic entity in 1964 by the 
American Rheumatism Association (later American College of Rheumatology) (Blumberg, 
1964). In the forthcoming years it has become clear that PsA belongs to the spondyloarthritis 
(SpA) family that comprises several heterogeneous clinical conditions. These are Ankylosing 
Spondylitis, Reactive Arthritis (which occurs after bacterial infections), Spondyloarthritis 
associated to Chronic Inflammatory Bowel Diseases (Crohn´s disease and Ulcerative 
Colitis), Undifferentiated Spondyloarthritis, and juvenile forms (figure 1). The term 
spondyloarthritis relates to inflammatory manifestations of peripheral and spinal joint 
structures. The Spondyloarthitides are defined by classification criteria (Sieper, 2009; Zeidler 
2011, Rudwaleit 2011). The main clinical manifestation will trigger the main group for each 
disease entity may have varying degrees of articular, spinal, and extraaticular 
manifestations. Furthermore, extraarticular inflammatory manifestations may also occur at 
different intensity levels. However, it needs to emphasized that classification criteria are not 
diagnostic criteria. Classification criteria were developed for clinical studies in order to 
include rather homogenous disease manifestations. In daily clinical practice it may occur 
that although the classification criteria are not fully met, the patient still may be allocated to 
a certain disease entity. 
 
Peripheral joint 
manifestations 
Spinal manifestations Extra-articular Manifestations 
Arthritis Spondylitis Uveitis, Scleritis, Conjunctivitis 
Enthesitis Enthesitis Psoriasis
Bursitis Sacroiliac joint arthritis Urethritis
Tendosynovitis Facet joint arthritis Inflammatory bowel disease 
Erosive-proliferative joint 
destruction 
Bony ankylosis Periodontitis with dental loss 
Table 1. Clinical manifestation of the Spondyloarthritides, which may be present in all the 
different disease entities (Fig. 1). 
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Fig. 1. Clinical entities of Spondyloarthritis. The overall disease group is the 
Spondyloarthritis, which comprises 6 distinct diseases. Psoriasis Arthritis is one disease 
entity of the group. Common abbreviations are given in parenthesis. 
In clinical practice, articular and extraarticular manifestations overlap quite frequently 
among the SpA diseases. Initially, the clinical manifestations of PsA were collected and a set 
of manifestations was proposed as classification criteria by Moll and Wright in 1973 (Moll, 
1973). These described clinical features were considered to be “Psoriatic Arthritis”. 
However, over the following years, 6 modified classification criteria for PsA (Bennet, 1979; 
Dougados, 1991; Fournie, 1999; Gladman, 1987; McGonagle, 1999; Vasey, 1984) have been 
proposed by different research groups in order to differentiate between the different disease 
entities (Taylor, 2002). As in the Moll and Wright criteria proposal, these criteria mainly 
have been established in groups of patients with classical and fully developed disease 
manifestations. The validity of these criteria have never been formally proven in studies. 
Formal prove of PsA criteria was done in 2006 with the publication of the CASPAR 
(Classification of Psoriasis Arthritis Study Group)-Criteria (Taylor, 2006) as a joint project of 
the EUAR and ACR. As with the other above mentioned 7 criteria sets, the CASPAR criteria 
also were established in a group of patients with long standing psoriasis arthritis (mean 
disease duration of greater than 10 years (Taylor, 2006). As we know that chronic 
inflammatory arthritis like Rheumatoid Arthritis (RA) and PsA can destroy joints and cause 
significant disability (see Tab. 1) we need to diagnose arthritis before destruction of tissue 
has taken place. For this reason, in RA, arthritis classification criteria have just been revised 
to also classify early RA (Aletaha, 2010). Next to the new RA early classification criteria, the 
newly proposed classification criteria for spinal spondyloarthritis now include MRI 
Spondylo-
arthritis 
(SpA) 
Ankylosing 
Spondylitis 
(AS) 
Association 
with Crohn´s 
Disease / 
Colitis ulcerosa 
Psoriasis 
Arthritis 
(PsA) 
Reactive 
Arthritis 
(ReA) 
Undifferentiated 
Spondylitis 
Juvenile 
forms 
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diagnostics of the sacroiliac joints (Rudwaleit, 2009). Bone marrow edema around the 
sacroiliac joints seen in MRI in water sensitive squences, i.e. STIR (short tau inversion 
recovery, T1 plus contrast media) detects inflammatory processes significantly earlier than 
actual joint destruction can be seen on conventional X-ray films. 
However, we still do not have validated early PsA criteria and early PsA most times does 
not present with the classical, fully developed clinical picture as is described in our 
textbooks.  
This book chapter is dedicated to discuss why we need to detect PsA early and will answer 
the question of how patients with psoriasis can be screened for possible early peripheral and 
spinal arthritis manifestations. Suggestions on how cooperation between dermatologists and 
rheumatologists can be effectively set up will be given at the end. 
2. Why is early detection of inflammatory processes important? 
2.1 The earlier the better or time is joint function 
Early detection and treatment of chronic inflammatory joint disease has been shown in 
numerous reports to correlate with better long-term outcome in rheumatoid arthritis (van 
der Bijl, 2007; Verstappen, 2007). Severity of joint destruction and loss of quality of life in 
PsA has been shown to be similar to RA (Husted, 2001; Rahman, 2001). Therefore, many 
aspects in PsA may be compared with aspects in RA. As depicted in figure 2, the chronic 
inflammatory process begins with an undulating situation of clinical and subclinical 
manifestations of joint pain with or without swelling. A trigger event then sets off the 
clinical manifest chronic inflammatory course. Joint destruction begins very early after this 
event. If the inflammatory process is not stopped, the natural disease course will occur with 
more or less destruction of joint structures.  
 
Fig. 2. Time course of the development of PsA. The earlier detection and treatment of 
arthritis takes place, the better the outcome in the following years will be, adapted according 
to (Machold, 1998).  
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However, if we treat to the target of remission and control the inflammatory process, it is 
possible to prevent or slow down the destructive process. We have plenty of evidence for 
this targeted approach for RA as reviewed elsewhere (Schoels, 2010). Furthermore, 
recommendations for physicians (Smolen, 2010) and patients (de Wit, 2011) on how to treat 
to the target of remission have recently been published. Very likely, the targeted approach is 
also true for PsA, because PsA also shows destructive disease courses and we use the same 
outcome measures than for RA. However, this has not yet been formally proven as has been 
for RA.  
Inflammation of articular structures always is coupled with loss of function. Early in the 
disease course inflammation and loss of function correlate very well. This means, if 
inflammation is suppressed, function is completely regained. However, the longer the 
inflammatory process goes on, the more fibrotic and destructive changes occur which are 
not reversible (Aletaha, 2006). This implies that effective suppression of inflammation will 
not result in full regain of function anymore (figure 3). Furthermore, fibrotic tissue may 
cause destruction by itself thus uncoupling the destructive process from classic immune 
mediated mechanisms (Neumann, 2006). 
 
Fig. 3. Correlation of inflammation (black), loss of function (yellow) and joint destruction 
(blue) with time. Very early in the inflammatory process loss of joint function is tightly 
correlated with the degree of inflammation. In this phase, complete reduction of joint 
inflammation will restore joint function. However, the longer the inflammatory process goes 
on, the more destruction of joint structures will occur along with continuously more 
irreversible loss of function and destruction. Finally, there may occur an uncoupling of 
inflammation and irreversible joint destruction with loss of function, adapted according to 
(Kirwan, 2001). 
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2.2 Chronic inflammation confers a cardiovascular risk factor by itself  
An upcoming discussion is that chronic inflammatory processes enhance the cardiovascular 
risk to a similar extend like the classical known risk factors diabetes, hypertension, 
hyperlipidemia, obesity, smoking and genetics (van Halm, 2009). This implies that treatment 
of inflammation may be similar important to the treatment of the classical cardiocascular 
risk factors in order to reduce the overall cardiovascular risk. Prospective studies on 
reduction of cardiovascular risk by anti-inflammatory treatment are still pending but it was 
shown retrospectively that effective reduction of inflammation with combination therapy of 
methotrexate and anti-TNF (Tumor Necrosis Factor) medication may reduce the risk for the 
first cardiovascular event (Cugno, 2010). 
As in RA the cytokine TNF plays an important role in the pathophysiological mechanism of 
Ps and PsA. The prothrombotic effects of TNF in cardiovascular disease are discussed in a 
recent review and may play an important role in the about 4 fold enhanced cardiovascular 
risk compared with the normal population (Jacobsson, 2005). However, Ps and PsA patients 
seem to additionally have an increased prevalence of cardiovascular risk factors such as 
smoking, hypertension, raised levels of homocysteine, excessive alcohol consumption and 
metabolic syndrome compared to the normal population (Tobin, 2010). Therefore, it cannot 
be finally answered to what extend chronic inflammation of the skin, joints, and spine in 
Ps/PsA add to an enhanced cardiovascular risk. 
2.3 Health care costs of PsA are high 
Another reason for early detection of PsA is health care costs. PsA shows increasing costs 
with the duration of the disease. This seems to mainly be due to the rising risk of work 
disability. However, the association of work disability and disease duration has not very 
well been studied up to day. Only 3 studies were published on this topic (Mau, 2005; 
Verstappen, 2010) and one review gets to the conclusion that the data is too heterogeneous 
to draw hard conclusions (Tillett, 2011). Nevertheless the study of Mau et al. describes a 
reduction of the standard employment rate in PsA patients from 0,94 to 0,7 within 5 years. 
Functional status seems to be the most important factor to predict total costs. Zink et al. 
summarize that patients with a poor functional status of 50% (HAQ of more than 1,7) cost 
more than double compared to patients with a good functional status (functional status of 
70% or HAQ less than 1,2) (Zink, 2006).  
2.4 Psychosomatic comorbidity is important to consider 
Finally, the psychological and psychiatric comorbidities resulting from the cutaneous 
stigmatization and the painful, debilitating arthritic manifestations of joint and spine add to 
the disease burden of PsA (Devrimci-Ozguven, 2000; Esposito, 2006). There seems to be no 
difference in depression rate among sex and age of patients with PsA. Effective therapy of 
cutaneous manifestations and arthritis may reduce depressive disorders, which will 
significantly reduce health costs and therefore needs to be balanced against the high costs of 
modern treatment with biologics. 
3. How can patients with PsA be identified in daily clinical routine? 
In clinical practice, psoriatic patients with a dominant skin manifestation primarily consult 
dermatologists and patients with a dominant peripheral or spinal manifestation primarily 
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consult rheumatologists or orthopedics. However, the vast majority of Ps patients gather 
within the dermatology setting. Therefore, it seems rational to screen patients for arthritic 
manifestations in the dermatology setting.  
From July 2005 until October 2008, we validated and established the self-administered 
patient-screening questionnaire GEPARD (GErman Psoriasis ARthritis Diagnostic 
questionnaire) to detect PsA in psoriatic patients seeking primarily dermatologic care 
(Härle, 2010) (Tab. 2 and www.kkm-mainz.de/rheumatologie). In order to keep the 
questionnaire simple, only dichotomous answers (yes/no) were used. The twelve questions 
were derived from discussions about appropriate questions among the authors and 
additional advice provided by other experienced rheumatologists. Questions number 1 to 4 
relate to clinical signs of arthritis but do not necessarily impose a momentary active state of 
arthritis by asking if the patient ever had these signs. It was considered that these questions 
take into account the remitting and relapsing nature of PsA. We considered the detection of 
these patients being especially important in the context of a longitudinal follow-up of 
fluctuating arthritis, which might eventually lead to establishing prognostic parameters for 
PsA. Questions number 5 to 8 pertain to arthritis in a more indirect way by relating to the 
discomfort caused by joint pain or dysfunction. Questions number 9 to 13 relate to the 
clinical signs of inflammatory back pain which can be associated with PsA. An additional  
 
# Question Yes No 
1 Have you ever had joint pain accompanied by swelling?   
2 Have you ever had a completely swollen digit or toe?   
3 Have you ever had joint pain accompanied by redness of that 
joint? 
  
4 Do your joints feel stiff after waking up in the morning?   
5 Have you ever thought of having a joint disease?   
6 Have you ever consulted a doctor because of your joint 
problems? 
  
7 Have you ever received the diagnosis of "arthritis"?   
8 Do you take pain medication for your joint pain?   
9 Do you suffer from back- or buttock pain? If yes, does/is this 
pain…. (please, answer questions 8a to 8d) 
  
10 … most intense in the early morning hours?   
11 … improve through exercising or moving around?   
12 … persist while resting?   
13 … accompanied by back stiffness in the morning hours?   
14 If you answered one of the above questions with “YES”: 
Since when do you have these complaints? 
More than 
1 week 
More than 
1 month 
More than 
3 months 
More than 
6 months 
More than 
1 year 
More than 
3 years 
More than 
5 years 
Table 2. The GEPARD questionnaire targets arthritic complaints of peripheral joints and 
spinal manifestations in addition of duration of arthritic symptoms thus enableing early 
detection of PsA. The patient alone answers the questionnaire. The physician or assistant 
counts the positive answers. The cut-off value of equal or more than 4 positive answers 
showed a sensitivity of 89% and a specificity of 73% to detect PsA in Ps patients 
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question related to the time period since the first occurrence of complaints lasting from one 
week up to more than 5 years in order to detect early PsA manifestations. In the statistical 
evaluation of the study, we calculated a cut-off value of greater than or equal to 4 positive 
answered questions. This cut-off showed a sensitivity of 89% and a specificity of 73% to 
detect PsA in Ps patients (Härle, 2010). 
In the final evaluation, we clinically evaluated 54 patients. These patients were selected by 
the GEPARD questionnaire from dermatology outpatient clinics. We found 43 patients who 
had some arthritic manifestations according to clinical examination, ultrasound, x-ray, MRI, 
and Technecium-Szintigraphy. This accounts for 79,6% patients being positive for PsA 
manifestation. This percentage of PsA among patients with Ps is in line with earlier 
publications (Sadek, 2007). Furthermore, 23 patients were first diagnosed as having PsA.  
According to the time duration of arthritic complaints we found 57% suffering over 4 years 
but 43% of patients below 4 years (figure 4) which may still be considered as being early 
arthritis. From these patients with complaints of less than 4 years 80% could be classified for 
PsA just by clinical examination according the CASPAR criteria without the use of 
sonography, x-ray, MRI, or szintigraphy (figure 5). Considering that the initial screening 
process was exclusively based on patients’ answers, without evaluation by a physician, the 
GEPARD patient - questionnaire is well suited for routine clinical usage. In addition, the 
screening tool does not consume additional time from the dermatologist but still enables 
him to identify patients who need to be referred to a rheumatologist for further evaluation 
of arthritic manifestation.  
 
Fig. 4. Pie chart of arthritis duration according to the GEPARD patient-questionnaire. Forty-
three percent suffered of symptoms of less than 4 years. Less than 4 years is considered to be 
early arthritis.  
57%
8%
9%
11% 15%
 Arthritis <1 year
 Arthritis >1<2 years
 Arthritis >2<3 years 
 Arthritis >3<4 years
 Arthritis >4 years
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Fig. 5. Distribution of arthritis, arthralgia and no complaints in percent of GEPARD patient-
questionnaire early arthritis patients (≤ 4 years). According to the CASPAR classification 
criteria, eighty percent were classified as having PsA. 
4. How could the cooperation between dermatologist and rheumatologist be 
set up? 
As described in the previous paragraphs screening of patients with Ps can easily be done by 
using the GEPARD patient self-administered questionnaire. In the case of equal or more 
than 4 positive answers in the questionnaire, the dermatologist may refer the patient to a 
cooperating rheumatologist. Since the end of the 90s most rheumatologists have set up an 
early arthritis schedule. With the GEPARD questionnaire the patient is already screened for 
arthritis and is more likely to have an arthritic manifestation. After the rheumatologic 
assessment the decision has to be made which discipline is advantageous to take the lead in 
guidance and treatment of the patient. Usually a cooperative way is chosen, taken into 
consideration that the general practitioner is the stearing physician for the other comorbid 
and social problems of the individual patient (figure 6).  
4%
16%
80%
 Arthritis
 Arthralgia
 No complaints
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In the case of leading arthritis, the consultation of the dermatologist is necessary to confirm 
the diagnosis of Ps by clinical means or by biopsy in unclear situations (figure 7). 
Furthermore, topical treatment may be instituted if systemic therapy of PsA does not lead to 
full treatment success of the skin. The same treatment cycle as described before is necessary 
in order to treat all facets of PsA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Flow chart of possible cooperation among the medical disciplines. Screening starts 
in the dermatology practice by using the GEPARD patient self-administered 
questionnaire. 
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Fig. 7. Flow chart of possible cooperation among the medical disciplines. In the case of 
suspected psoriatic manifestation or in the case of suboptimal treatment response of Ps by 
systemic therapy the rheumatologist confers the patient to the dermatologist for further 
evaluation. 
5. Summary 
Considering all the many facets of PsA and the different diagnostic and therapeutic 
strategies is the art of modern medicine and good clinical practice. We need to understand 
the context of inflammatory skin, joint, and spine manifestations with mental health, extra 
articular problems and economical considerations. This can only be accomplished by good 
cooperation between dermatologist and rheumatologist in addition to the comprehensive 
care by the general practitioner, internist, and psychological disciplines (figure 8). 
www.intechopen.com
Detecting Psoriasis Arthritis Early in the Disease Course – Why This  
is Important and How Dermatologists and Rheumatologists Can Successfully Cooperate? 75 
 
Fig. 8. Interdisciplinary, holistic view of Ps and PsA. 
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